Literature DB >> 30368048

Cross-section measurement of 44mSc,47Sc, 48Sc and 47Ca for an optimized 47Sc production with an 18 MeV medical PET cyclotron.

Tommaso Stefano Carzaniga1, Saverio Braccini2.   

Abstract

Novel medical radioisotopes for both diagnostic and therapy are essential for the future development of personalized nuclear medicine. Among them, radiometals can be used to label both proteins and peptides and encompass promising theranostic pairs. The optimized supply of radiometals in quantity and quality for clinical applications represents a scientific and technological challenge. 47Sc is a β- emitter that forms a theranostic pair together with one of the β+ emitters 43Sc or 44Sc. It can be produced at a medical cyclotron by proton bombardment of an enriched calcium oxide target. The parasite production of 48Sc undermines the 47Sc purity, which strongly depends on the energy of protons impinging the target and on the thickness of the target material. For this purpose, an accurate knowledge of the production cross-sections is mandatory. In this paper, we report on the measurement of the cross-section of the reactions 44Ca(p,n)44 mSc,48Ca(p,n)48Sc, 48Ca(p,2n)47Sc and 48Ca(p,pn)47Ca using natCaCO3 targets performed at the Bern University Hospital cyclotron laboratory. On the basis of the obtained results and of the isotopic composition of commercially available enriched target materials, the thick target yields and the purity were calculated to assess the optimal irradiation conditions.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cross-section; Medical cyclotrons; Scandium; Theranostics; Therapeutic radioisotopes

Year:  2018        PMID: 30368048     DOI: 10.1016/j.apradiso.2018.10.015

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  1 in total

Review 1.  Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.

Authors:  R Mikolajczak; S Huclier-Markai; C Alliot; F Haddad; D Szikra; V Forgacs; P Garnuszek
Journal:  EJNMMI Radiopharm Chem       Date:  2021-05-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.